Drugs / ABO-CoV.617.2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05434585 | Jul → Oct 2022 | COVID-19 | Suzhou Abogen Biosciences Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABO-CoV.617.2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05434585 ↗ |
| Route | Intramuscular | “Intramuscularly injecting 15 μg of ABO-CoV.617.2 into lateral deltoid” NCT05434585 ↗ |